D

Daewoong Co Ltd
KRX:003090

Watchlist Manager
Daewoong Co Ltd
KRX:003090
Watchlist
Price: 22 900 KRW -0.43% Market Closed
Market Cap: 936.4B KRW
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Daewoong Co Ltd stock under the Base Case scenario is 55 986.36 KRW. Compared to the current market price of 22 900 KRW, Daewoong Co Ltd is Undervalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
55 986.36 KRW
Undervaluation 59%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

0.5
P/S
P/S
Price to Sales
0.5
vs History
61
vs Industry
84
Median 3Y
0.4
Median 5Y
0.5
Industry
2.6
Forward
0.4
More Details
11.4
P/E
P/E
Price to Earnings
11.4
vs History
46
vs Industry
32
Median 3Y
7
Median 5Y
10.9
Industry
21.4
Forward
6.5
More Details
4.4
P/OCF
P/OCF
Price to OCF
4.4
vs History
69
vs Industry
48
Median 3Y
4.6
Median 5Y
6.1
Industry
16.4
More Details
10.5
P/FCFE
P/FCFE
Price to FCFE
10.5
vs History
65
vs Industry
21
Median 3Y
10
Median 5Y
17.4
Industry
22.5
More Details
0.9
P/B
P/B
Price to Book Value
0.9
vs History
57
vs Industry
65
Median 3Y
0.9
Median 5Y
1
Industry
2.2
More Details
0.6
EV/S
EV/S
Enterprise Value to Sales
0.6
vs History
44
vs Industry
83
Median 3Y
0.5
Median 5Y
0.6
Industry
2.8
Forward
0.6
More Details
1.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.1
vs History
49
vs Industry
82
Median 3Y
1
Median 5Y
1.1
Industry
5.4
More Details
3.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
3.4
vs History
60
vs Industry
49
Median 3Y
3.2
Median 5Y
3.5
Industry
12.8
Forward
3.3
More Details
4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
4
vs History
61
vs Industry
47
Median 3Y
3.9
Median 5Y
4.5
Industry
16.4
Forward
4.1
More Details
5.9
EV/OCF
EV/OCF
Enterprise Value to OCF
5.9
vs History
63
vs Industry
45
Median 3Y
5.7
Median 5Y
6.9
Industry
15.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
28
Median 3Y
-6.4
Median 5Y
21.5
Industry
18.3
More Details
0.5
EV/IC
EV/IC
Enterprise Value to IC
0.5
vs History
44
vs Industry
75
Median 3Y
0.5
Median 5Y
0.5
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Daewoong Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Daewoong Co Ltd
KRX:003090
936.4B KRW 0.5 11.4 3.4 4
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.8 54.2 36.6 39.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
490.8B USD 5.3 19.5 16 20.7
CH
Roche Holding AG
SIX:ROG
249.1B CHF 4 26.4 11.9 13.4
UK
AstraZeneca PLC
LSE:AZN
215.5B GBP 4.9 30 108.4 158.7
CH
Novartis AG
SIX:NOVN
198.2B CHF 4.4 17 10.9 14
US
Merck & Co Inc
NYSE:MRK
251.7B USD 3.9 13.2 9.4 11.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4 12.2 8.5 9.9
IE
Endo International PLC
LSE:0Y5F
202B USD 87.1 -69.1 320.4 803.4
US
Pfizer Inc
NYSE:PFE
143.5B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
KR
D
Daewoong Co Ltd
KRX:003090
Average P/E: 22.1
11.4
48%
0.2
US
Eli Lilly and Co
NYSE:LLY
54.2
50%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.5
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.4
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
38%
0.8
CH
Novartis AG
SIX:NOVN
17
18%
0.9
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.2
7%
1.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
31%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
D
Daewoong Co Ltd
KRX:003090
Average EV/EBITDA: 398.1
3.4
10%
0.3
US
Eli Lilly and Co
NYSE:LLY
36.6
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
8%
2
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
10.9
6%
1.8
US
Merck & Co Inc
NYSE:MRK
9.4
7%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
8.5
6%
1.4
IE
E
Endo International PLC
LSE:0Y5F
320.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
D
Daewoong Co Ltd
KRX:003090
Average EV/EBIT: 1 707.9
4
9%
0.4
US
Eli Lilly and Co
NYSE:LLY
39.2
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.7
14%
1.5
CH
Roche Holding AG
SIX:ROG
13.4
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
158.7
22%
7.2
CH
Novartis AG
SIX:NOVN
14
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.2
9%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
803.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 298,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.